Pharmaceuticals company Solara Active Pharma Sciences announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from Operations: For Q4FY26, revenue stood at Rs. 387.29 crore, representing a YoY increase of 41.86% from Rs. 273.01 crore in Q4FY25 and a QoQ increase of 10.97% from Rs. 349.00 crore in Q3FY26. For the full year FY26, revenue was Rs. 1,368.98 crore, a YoY increase of 6.64% compared to Rs. 1,283.76 crore in FY25. Total Income: Total income for Q4FY26 was Rs. 391.98 crore, compared to Rs. 278.96 crore in Q4FY25 (YoY increase of 40.51%) and Rs. 349.00 crore in Q3FY26 (QoQ increase of 12.32%). Annual total income for FY26 reached Rs. 1,375.14 crore versus Rs. 1,292.08 crore in FY25. Net Profit / Loss: The Group reported a Net Profit of Rs. 9.60 crore in Q4FY26, compared to a Net Loss of Rs. 2.10 crore in Q4FY25 and a Net Loss of Rs. 17.43 crore in Q3FY26. For the full year FY26, the Group incurred a Net Loss of Rs. 7.41 crore, compared to a Net Profit of Rs. 0.54 crore in FY25. Total Comprehensive Income: Total comprehensive income for Q4FY26 was Rs. 10.10 crore, compared to a loss of Rs. 2.72 crore in Q4FY25. For FY26, total comprehensive loss stood at Rs. 4.56 crore versus an income of Rs. 1.52 crore in FY25. Standalone Financial Highlights: Revenue from Operations: Standalone revenue for Q4FY26 was Rs. 387.29 crore, up 41.86% YoY from Rs. 273.01 crore and up 10.97% QoQ from Rs. 349.00 crore. Annual revenue for FY26 stood at Rs. 1,368.98 crore compared to Rs. 1,283.76 crore in FY25. Total Income: Total income for Q4FY26 was Rs. 391.71 crore, compared to Rs. 278.96 crore in Q4FY25 and Rs. 349.00 crore in Q3FY26. Net Profit / Loss: Standalone Net Profit for Q4FY26 was Rs. 9.73 crore, as against a Net Loss of Rs. 4.88 crore in Q4FY25 and a Net Loss of Rs. 17.42 crore in Q3FY26. For the full year FY26, the company reported a Net Loss of Rs. 7.24 crore compared to a Net Loss of Rs. 1.08 crore in FY25. Business Highlights: Segment Performance: The Group’s operations relate to only one reportable segment, namely Active Pharmaceutical Ingredient (API). Strategic Initiatives: The Board has discussed a proposal to explore the ‘demerger of the CRAMS and Polymers business into an independent listed entity’ and granted in-principle approval for the same. Rights Issue: The company offered 1,19,98,755 equity shares at Rs. 375 per share, aggregating to Rs. 449.95 crore. As of March 31, 2026, the company has raised Rs. 312.79 crore from the issue, with a final call notice sent for the remaining balance of Rs. 134.99 crore. Subsidiary Developments: Incorporated a wholly owned subsidiary, Synthix Global Pharma Solutions Limited, on April 29, 2025. Approved the closure of Solara Active Pharma Sciences LTDA, Brazil, effective September 16, 2025, as there were no operations. Exceptional Items: The Group recorded an exceptional item impact of Rs. 5.89 crore for the year FY26 related to gratuity and compensated absences impact under new labour codes. Sandeep Rao Managing Director & CEO said: "Our overall performance for Q4'26 reflects a sequential growth of 12% and YoY growth of 40%. We recorded the highest Revenue, Gross margin & EBITDA in the last eight quarters. Notably, the Base business is already demonstrating superior profitability, operating at a ~26% EBITDA margin with gross margins of ~54% which reinforces the objective we established at the start of the year to pivot the business from a phase of reset to one defined by sustainable, profitable and reliable growth. However, we continue to be challenged by the Ibuprofen business which is demonstrating weak profitability, operating at a negative 21% EBITDA margin with gross margins of ~23%. Given the persistent headwinds on this business, we have appointed bankers to evaluate strategic options for this business to ensure optimal long-term value creation. Despite the significant crisis in the middle east and its impact on global business, the underlying fundamentals of the base business continue to remain strong, supported by a resilient operating model and a healthy product mix across regulated markets." Result PDF